1. What is the projected Compound Annual Growth Rate (CAGR) of the Radiotheranostics Market?
The projected CAGR is approximately 18.5 %.
+1 2315155523
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
Radiotheranostics MarketRadiotheranostics Market by Radioisotopes (Lutetium-177, Radium-223, Iodine-131, Others), by Application (Neuroendocrine Tumors, Prostate Cancer, Others), by End-user (Hospitals & Clinics, Diagnostic Centers, Others), by North America (U.S., Canada) Forecast 2025-2033
The Radiotheranostics Market size was valued at USD 1.80 USD Billion in 2023 and is projected to reach USD 5.91 USD Billion by 2032, exhibiting a CAGR of 18.5 % during the forecast period. Radiotheranostics delivers a protein complex that is for both imaging and therapy utilizing one molecule which is a radically new approach in personalized medicine. They comprise pairs, which are a diffuse group of theragnostic ᅳ like those with Gallium-68 and Lutetium-177, used in nuclear medicine for imaging and therapy respectively. To note, they display a high degree of selectivity, ensuring that they have no effect on other dimensions of the therapy being administered. With this method, therapy progress is able to be measured all the time, which helps to tailor health care to best suit the patient. Radiotheranostics, a merger of imagery, surgery, and radiation, is currently adopted by oncologists, neurologists, and cardiologists as a means to offer patient-specific care. One of its greatest strengths is its vast repertoire of applications and that is why it occupies a central place in helping to arrive at customized treatments. That, on the other hand, offers great prospects to sick people for better results without increasing their safety and efficacy risks.
December 2023: ITM Isotope Technologies Munich SE (ITM) acquired an exclusive license for radiolabeled folate derivatives for therapeutic and diagnostic applications.
June 2023: ARICEUM THERAPEUTICS acquired Theragnostics Ltd., a developer of radio-labeled PARP inhibitors.
March 2023: Radiopharm Theranostics acquired Pharma15 Corporation, a developer of radiopharmaceuticals for prostate cancer.
November 2022: Clarity Pharmaceuticals received U.S. FDA approval for its IND application for SAR-Bombesin in prostate cancer.
August 2022: MD Anderson Cancer Center and Radiopharm Theranostics launched Radiopharm Ventures for developing radiopharmaceutical therapeutic products.
Radioisotopes:
Application:
End-user:
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 18.5 % from 2019-2033 |
| Segmentation |
|
Note*: In applicable scenarios
Primary Research
Secondary Research
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
The projected CAGR is approximately 18.5 %.
Key companies in the market include Bayer AG (Germany), Novartis AG (Switzerland), Lantheus Holdings, Inc. (U.S.), Telix Pharmaceuticals Limited (Australia), GE Healthcare (General Electric Company) (U.S.), Cardinal Health (U.S.), ARICEUM THERAPEUTICS (Germany), Isotopia Molecular Imaging Ltd. (Israel), Radiopharm Theranostics (Australia).
The market segments include Radioisotopes, Application, End-user.
The market size is estimated to be USD 1.80 USD Billion USD Billion as of 2022.
Rising Prevalence of Cancers to Drive Market Growth.
Increasing Collaborations Among Key Players to Enhance Patient Care in Theranostics.
Short Half-Life of Radioisotopes to Restrain Market Expansion.
December 2023: ITM Isotope Technologies Munich SE (ITM), a Germany based radiopharmaceutical biotechnology company, announced that it had gained an exclusive license for radiolabeled folate derivatives to be used in therapeutic and diagnostic applications for malignant tumors.
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4850, USD 5850, and USD 6850 respectively.
The market size is provided in terms of value, measured in USD Billion.
Yes, the market keyword associated with the report is "Radiotheranostics Market," which aids in identifying and referencing the specific market segment covered.
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
To stay informed about further developments, trends, and reports in the Radiotheranostics Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.